Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for administration of the drug to patients.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest ...

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

The investigators conducted a prospective interventional study to determine the therapeutic anatomic and functional effects ...

Labtician Ophthalmics has announced the commercial launch of Lab TRIACTIV, an artificial tear designed to redefine dry eye ...

Brazilian researchers conducted a study comparing two treatments for postoperative endophthalmitis. They found that pars ...

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...

Refractive cataract surgery has been transformed by advanced IOL technology, including extended and full-range vision lenses, ...

To create lasting change, ophthalmology must embrace the impact of sponsorship and advocacy—empowering the next generation of ...